{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:19Z","timestamp":1791994579084,"version":"4.4.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pemphigus is a rare autoimmune disease characterized by the production of pathogenic autoantibodies against desmosomal adhesion proteins, desmoglein 1 and 3. The pathophysiological process leads to the development of blisters and erosions on mucosal and\/or skin surfaces as the main clinical manifestation of the disease. Rituximab emerged as the first-line therapeutic option for pemphigus due to its ability to induce remission by depleting peripheral B lymphocytes. Our aim was to assess the efficacy of rituximab in the treatment of patients in Croatia. A single-center, retrospective study was conducted on 19 patients treated with rituximab following a rheumatoid arthritis dosing protocol between October 2015 and March 2021, with a mean follow-up of 24.1 months. After the first rituximab cycle, two patients achieved complete remission off therapy (10.5%), and six patients achieved complete remission on minimal therapy (31.6%). Partial remission was observed among ten patients (52.6%). Eight patients (44.4%) relapsed after the first rituximab cycle. The mean relapse time was 21 months. Seven patients received two rituximab cycles, and three patients received three cycles. Overall, 13 out of 19 patients experienced complete remission at some point during the study, while there were no non-responders after the rituximab treatment. No statistically significant associations were observed between age, sex, type of disease involvement and clinical remission, either on or off therapy. A steady decrease in anti-desmoglein 1 and anti-desmoglein 3 levels was measured among all patients following rituximab treatment. One patient experienced a treatment-related adverse event of infectious etiology (cellulitis). One patient died following the first rituximab cycle, with the cause of death likely not to be associated with the treatment. Rituximab is an effective disease-modifying agent in the treatment of pemphigus with the main benefit of reducing corticosteroid exposure and steroid-related side effects among pemphigus patients. However, a feature of rituximab therapy is high relapse rates and the need for repeated treatment cycles to achieve complete remission. Developing an optimal protocol for rituximab treatment and finding suitable markers for predicting relapse will improve the management of pemphigus patients.<\/jats:p>","DOI":"10.3389\/fimmu.2022.884931","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T04:32:32Z","timestamp":1651552352000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Jo\u0161ko","family":"Mi\u0161e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines Lako\u0161","family":"Juki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Marinovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2011.07.003","article-title":"Autoimmune Blistering Diseases: Incidence and Treatment in Croatia","volume":"29","author":"Marinovic","year":"2011","journal-title":"Dermatol Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: Current and Future Therapeutic Strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5826\/dpc.1003a50","article-title":"Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment","volume":"10","author":"Di Lernia","year":"2020","journal-title":"Dermatol Pract Concept"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD 20 Chimeric Monoclonal Antibody (Rituximab) for the Treatment of Recalcitrant, Life-Threatening Pemphigus Vulgaris With Implications in the Pathogenesis of the Disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-Line Rituximab Combined With Short-Term Prednisone Versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicentre, Parallel-Group, Open-Label Randomised Trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and Management of Pemphigus: Recommendations of an International Panel of Experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus Statement on Definitions of Disease, End Points and Therapeutic Response for Pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/09546634.2019.1617831","article-title":"Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study","volume":"32","author":"Toosi","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12671","article-title":"Anti-Desmoglein-1 Levels as Predictor of Prednisolone Tapering in Pemphigus Vulgaris Patients Treated With Rituximab","volume":"31","author":"Balighi","year":"2018","journal-title":"Dermatol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2340\/00015555-3649","article-title":"Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris","volume":"100","author":"Baum","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-Term Remissions of Severe Pemphigus After Rituximab Therapy are Associated With Prolonged Failure of Desmoglein B Cell Response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16561","article-title":"Long-Term Outcomes of Rituximab Therapy in Pemphigus","volume":"34","author":"Shimanovich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.11.024","article-title":"Rituximab as First-Line Adjuvant Therapy for Pemphigus: Retrospective Analysis of Long-Term Outcomes at a Single-Center","volume":"78","author":"Vinay","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14546","article-title":"Rituximab as an Adjuvant Therapy for Pemphigus: Experience in 61 Patients From a Single Center With Long-Term Follow-Up","author":"Sharma","year":"2019","journal-title":"Int J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/ijdvl.IJDVL_848_17","article-title":"Effectiveness and Safety Analysis of Rituximab in 146 Indian Pemphigus Patients: A Retrospective Single-Center Review of Up to 68 Months Follow-Up","volume":"86","author":"De","year":"2020","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12678","article-title":"An Assessment of Treatment History and its Association With Clinical Outcomes and Relapse in 155 Pemphigus Patients With Response to a Single Cycle of Rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant Rituximab Therapy of Pemphigus: A Single-Center Experience With 31 Patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-Analysis of Different Regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13103","article-title":"Rituximab in the Treatment of 38 Patients With Pemphigus With Long-Term Follow-Up","volume":"6","author":"Currimbhoy","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA Testing of Anti-Desmoglein 1 and 3 Antibodies in the Management of Pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing Biomarkers for Predicting Clinical Relapse in Pemphigus Patients Treated With Rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111555","article-title":"Pemphigus-The Crux of Clinics, Research and Treatment During the COVID-19 Pandemic","volume":"9","author":"Marinovic","year":"2021","journal-title":"Biomedicines"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00218","article-title":"The Evolving Story of Autoantibodies in Pemphigus Vulgaris: Development of the \u201cSuper Compensation Hypothesis\u201d","volume":"5","author":"Sinha","year":"2018","journal-title":"Front Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01190","article-title":"Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris","volume":"9","author":"Amber","year":"2018","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B Cell Depletion Therapies in Autoimmune Diseases: Advances and Mechanistic Insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.717","article-title":"Autoreactive B Cell Differentiation in Diffuse Ectopic Lymphoid-Like Structures of Inflamed Pemphigus Lesions","volume":"140","author":"Zhou","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-Cell Subpopulations in Humans and Their Differential Susceptibility to Depletion With Anti-CD20 Monoclonal Antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13757","article-title":"Adjuvant Rituximab Treatment for Pemphigus: A Retrospective Study of 45 Patients at A Single Center With Long-Term Follow Up","volume":"44","author":"Kim","year":"2017","journal-title":"J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dth.12763","article-title":"Rituximab Therapy in Pemphigus: A Long-Term Follow-Up","volume":"32","author":"Loi","year":"2019","journal-title":"Dermatol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.884931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T04:32:34Z","timestamp":1651552354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.884931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2022.884931"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.884931","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"article-number":"884931"}}